Global Dry Eye Syndrome Market 2015-2019

ドライアイ症候群治療薬の世界市場2015-2019

◆タイトル:Global Dry Eye Syndrome Market 2015-2019
◆商品コード:IRTNTR6905
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年8月26日
◆ページ数:70
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、ドライアイ症候群治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、ドライアイ症候群治療薬の世界市場規模及び予測、種類別分析、市場シェア、地域別分析、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About dry eye syndrome
Dry eye syndrome usually results in dryness of eyes due to deficient tear production or quick tear evaporation or deviation in tear uniformity. This syndrome is of two types: aqueous tear deficient dry eye and evaporative dry eye. In aqueous tear deficient dry eye, lacrimal glands do not produce enough tears, whereas meibomian gland dysfunction results in evaporative dry eye. Meibomian glands secrete lipids to slow tear evaporation and maintain tear stability. The symptoms include pain, redness, burning, and fatigue in the eye and decreased tolerance to continuous visual activity. Dry eye syndrome cannot be cured, but symptoms can be controlled. Teardrops and anti-inflammatory drugs are used in the treatment.

Technavio’s analysts forecast the global dry eye syndrome market to grow at a CAGR of 4.75% over the period 2014-2019.

[Covered in this report]
The report includes the present scenario and the growth prospects of the global dry eye syndrome market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of teardrops and anti-inflammatory drugs used in the treatment of dry eye syndrome.

Technavio’s report, Global Dry Eye Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation. The report includes a discussion of the key vendors operating in this market.

[Key regions]
• Americas
• APAC
• EMEA

[Key vendors]
• Alcon
• Allergan
• Otsuka Holdings
• Santen Pharmaceuticals

[Other prominent vendors]
• Acadia Pharmaceuticals
• Aciex
• Allostera Pharma
• arGentis
• Auven Therapeutics (Celtic)
• Bridge Pharma
• Can-Fite
• Cellzome

[Market Driver]
• Growing prevalence of dry eye syndrome
• For a full, detailed list, view our report

[Market challenge]
• Self-medication by patients
• For a full, detailed list, view our report

[Market trend]
• Growing awareness about the syndrome
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Disease overview
Understanding dry eye syndrome
Types of dry eye syndrome
Risk factors for dry eye syndrome
Signs and symptoms
Causes of dry eye syndrome
Epidemiology
Diagnosis
Disease management

PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 07: Pipeline analysis
Cyclokat
Diquas
EBI-005
MIM-D3
Lifitegrast
RGN-259
EBI-005
EGP-437

PART 08: Market segmentation by sub-type of dry eye

PART 09: Market segmentation by drug type
Oral antibiotics
Eye drops
Eye inserts
Eye ointments

PART 10: Geographical segmentation
Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors

PART 16: Key vendor analysis
Alcon
Allergan
Otsuka Holdings
Santen Pharmaceuticals

PART 17: Appendix
List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Regional prevalence of dry eye syndrome
Exhibit 03: Diagnosis of dry eye syndrome
Exhibit 04: Surgical options
Exhibit 05: Punctal plugs
Exhibit 06: Global dry eye syndrome market 2014-2019 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Market segmentation by sub-type of dry eye
Exhibit 09: Dry eye syndrome: pharmacologic therapy
Exhibit 10: Artificial tears: Different generations
Exhibit 11: Global dry eye syndrome market share 2014
Exhibit 12: Global dry eye syndrome: Key drivers
Exhibit 13: Impact of drivers
Exhibit 14: Global dry eye syndrome: Key challenges
Exhibit 15: Impact of drivers and challenges
Exhibit 16: Global dry eye syndrome: Emerging trends
Exhibit 17: Global dry eye syndrome market share analysis 2014
Exhibit 18: Alcon: Business strategy
Exhibit 19: Alcon: Distribution of sales by category 2014
Exhibit 20: Alcon: Region-wise sales distribution 2014 ($ millions)
Exhibit 21: Alcon: Region-wise sales distribution 2013 ($ millions)
Exhibit 22: Systane: Global sales 2011-2014 ($ millions)
Exhibit 23: Allergan: Business strategy
Exhibit 24: Eye care pharmaceuticals: Global sales 2011-2014 ($ millions)
Exhibit 25: Restasis: Global sales 2011-2014 ($ millions)
Exhibit 26: Santen Pharmaceuticals: Business strategy
Exhibit 27: Hyalein: Global sales 2011-2014 ($ millions)
Exhibit 28: Diquas: Global sales 2011-2014 ($ millions)
Exhibit 29: Prescription ophthalmics : Global sales 2011-2014 ($ millions)
Exhibit 30: Alcon: Business segmentation 2014
Exhibit 31: Allergan: Business segmentation by revenue 2014
Exhibit 32: Allergan: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 33: Allergan: Geographical segmentation by revenue 2014
Exhibit 34: Santen Pharmaceutical: Business/Product segmentation 2014 by revenue



【掲載企業】

Alcon, Allergan, Otsuka Holdings, Santen Pharmaceuticals, Acadia Pharmaceuticals, Aciex, Allostera Pharma, arGentis, Auven Therapeutics (Celtic), Bridge Pharma, Can-Fite, Cellzome


【資料のキーワード】

ドライアイ症候群(眼球乾燥症候群)、治療薬、パイプライン、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[ドライアイ症候群治療薬の世界市場2015-2019] (Global Dry Eye Syndrome Market 2015-2019 / IRTNTR6905)販売に関する免責事項
[ドライアイ症候群治療薬の世界市場2015-2019] (Global Dry Eye Syndrome Market 2015-2019 / IRTNTR6905)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆